DSM invests $25 million in Amyris
In California, Amyris, Inc. the industrial bioscience company, and Koninklijke DSM N.V., the global science-based company active in health, nutrition and materials, announced that they have agreed for DSM to make an equity investment in Amyris. At the same time, the companies will enter into a development cooperation focused on products for the global health and nutrition markets (including vitamins and other nutritional ingredients).
DSM has agreed to make an initial equity investment in Amyris of $25 million, translating into a shareholding of ~12%. Subject to the satisfaction of certain conditions, DSM may invest an additional $25 million in Amyris. The first tranche is expected to close on Thursday, 11 May 2017, with a second tranche, if approved by DSM’s Managing Board, expected to close within 90 days of the closing of the first tranche. As part of this investment, DSM will gain one board seat upon the closing of each tranche.
Category: Fuels
